sotrovimab
sotrovimab: developed by 1 company · 3 clinical trials tracked.
sotrovimab evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could sotrovimab → XNCR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 2 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| Xencor Inc (XNCR) early treatment of mild-to-moderate COVID-19 in adults and p… | Approved |
Clinical Trials (3)
Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
Primary endpoint: Rate of viral clearance for interventions relative to the no study arm (This is a superiority comparison)
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion
Primary endpoint: Confirmed symptomatic COVID-19 infection during treatment
Randomised Evaluation of COVID-19 Therapy
Primary endpoint: Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge)
Frequently asked questions
Who is developing sotrovimab?
sotrovimab is being developed by Xencor Inc.
How many clinical trials involve sotrovimab?
BioSniper tracks 3 clinical trials involving sotrovimab.